Senest opdateret: 16. nov. 2026, 00.00

ALK-Abelló A/S Exchange (CO, DKK)

ALK-B.CO

248.40
-0.40 (-0.16%)
HealthcareBiotechnology
Invester i dag
Invester i dag
1 års afkast (CAGR)
21.41%
3 års afkast (CAGR)
46.25%
5 års afkast (CAGR)
10.87%
10 års afkast (CAGR)
18.55%
Aktieanalyse

Adobe 2026 Q3 – Er det stemningen, der driver prisen?

Læs mere
Markedsværdi
50.08B
Pris/omsætning
7.33
Ent værdi
51.13B
Pris/bog
7.21
Udbytte afkast
0.00%
Vekst år
-
Udbyttevækst
-
FCF-udbetaling
18.84%
Efterfølgende P/E
36.93
PEG
-
Fremtidig P/E
33.89
EPS-vekst
116.41%

Oplysninger om aktier

iO Charts Blog

Hvad er en børs? Drift, aktører, eksempler

Læs mere

Aktiediagram

Loading...
Aktiekurs-data
Åbning249.00
Daglig høj250.00
Daglig lav247.60
Daglig volumen101K
Højeste gennem alle tider270.40
1 års analytiker estimat287.50
Beta0.75
EPS (TTM)6.11
Udbytte pr. aktie0.00
Ex-div dato17 Mar 2026
Næste dato for resultatpræsentation20 Feb 2026

Klar til at udnytte vækstpotentialet i ALK-Abelló A/S?

Tag det næste skridt i din portefølje.

Invester i dag

Nedsidepotensial

Loading...
Nedsidepotensial-data
ALK-B.COS&P500
Nuværende prisfald fra top notering-8.14%-3.17%
Højeste prisfald-82.39%-56.47%
Højeste efterår dato10 Aug 20119 Mar 2009
Gennemsnitlig fald fra toppen-34.11%-10.64%
Gennemsnitlig tid til nyt højdepunkt35 days12 days
Maks. tid til nyt højdepunkt3100 days1805 days
Nyheder
ALK-Abelló Pharmaceuticals Inc. Canada reported that neffy, a 2 mg epinephrine nasal spray for emergency allergic reactions, was reclassified in 2026 as a Schedule II product across Canada. This chang...
16. november 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference...
16. november 2026
ALK-Abelló raised its 2026 guidance, now targeting 16% to 17% revenue growth in local currencies and an EBIT margin around 27%, supported by all regions and products with tablets as the main driver. T...
16. oktober 2026
ALK-Abelló Pharmaceuticals Inc. Canada (ALK Canada) today announced that the Canadian Drug Expert Committee (CDEC) of Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse n...
1. oktober 2026
ALK-Abelló (CPSE:ALK B) has reshuffled its top ranks, appointing Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy, effective 1 October 2026, as investors wei...
23. september 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley...
11. september 2026
Alk-Abello AS (AKBLF) reports 18% revenue growth in Q2, driven by record tablet sales exceeding DKK1 billion, and raises full-year revenue outlook to 14%-16%.
20. august 2026
The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While ...
27. juli 2026
ALK will present phase II data from the ALLIANCE trial of its once-daily investigational sublingual immunotherapy (SLIT) tablet for peanut allergy1,2,3 at the American College of Allergy, Asthma & Imm...
12. november 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first nine months (Q3) of 2026 in the afternoon on Tuesday, 17 November 2026. The company will host a presentation for investo...
10. november 2026